| Issue Date | Title | Author(s) |
| Oct-2021 | Circularly permuted TRAIL (CPT) combined with Thalidomide and Dexamethasone in patients with relapsed/refractory Multiple Myeloma: a randomized, double-blind, placebo-controlled phase 3 study | Chen, Wenming; Xia, Zhongjun; Fang, Baijun; Fu, Chengcheng; Li, Wei; Yang, Linhua; Ke, Xiaoyan; Jiang, Hua; Weng, Jianyu; Liu, Li; Zhao, Yaozhong; Zhang, Xuejun; Liu, Aichun; Huang, Zhongxia; Shi, Qingzhi; Gao, Yuhuan; Chen, Xiequn; Pan, Ling; Cai, Zhen; Wang, Zhao; Wang, Yafei; Zhang, Yizhuo; Fan, Yaqun; Hou, Ming; Yang, Shifang |
| 2017 | Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study | Leng, Yun; Hou, Jian; Jin, Jie; Zhang, Mei; Ke, Xiaoyan; Jiang, Bin; Pan, Ling; Yang, Linhua; Zhou, Fang; Wang, Jianmin; Wang, Zhao; Liu, Li; Li, Wei; Shen, Zhixiang; Qiu, Lugui; Chang, Naibai; Li, Jianyong; Liu, Jing; Pang, Hongyan; Meng, Haitao; Wei, Peng; Jiang, Hua; Liu, Yan; Zheng, Xiangjun; Yang, Shifang; Chen, Wenming |
| Aug-2022 | Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthere (R)) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial | Shi, Yuankai; Zhang, Qingyuan; Hong, Xiaonan; Wang, Zhen; Gao, Yuhuan; Zou, Liqun; Cen, Hong; Gui, Lin; Li, Yufu; Feng, Jifeng; Wang, Zhao; Zhang, Mingzhi; Jin, Chuan; Zhang, Weihua; Hu, Jianda; Zheng, Chengyun; Zheng, Zhendong; Zhang, Liling; Chen, Shaoshui; Huang, Yunhong; Tang, Yun; Gao, Yajie; Hao, Miaowang; Li, Xiaoling; Chang, Chunkang; Yang, Haiyan; Wu, Hui; Shen, Lida; Ke, Xiaoyan; Zhang, Liangming; Xi, Yaming; Yang, Linhua; Xie, Liangzhi; Gai, Wenlin; Ji, Yanan |
| 2-Nov-2023 | Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF) | Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Suo, Shanshan; Yu, Wenjuan; Jin, Jie |
| 2024 | Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis | Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Wu, Liqing; Yin, Hewen; Suo, Shanshan; Yu, Wenjuan; Jin, Jie |
| 18-Dec-2024 | Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study | Zhang, Yi; Zhou, Hu; Suo, Shanshan; Zhuang, Junling; Yang, Linhua; He, Aili; Liu, Qingchi; Du, Xin; Gao, Sujun; Li, Yarong; Li, Yan; Chen, Yuqing; Wu, Wen; Zhu, Huanling; He, Guangsheng; Hong, Mei; Jiang, Qian; Jiang, Zhongxing; Jing, Hongmei; Wang, Jishi; Xu, Na; Yue, Lingling; Zheng, Cuiping; Zhou, Zeping; Jin, Chenghao; Li, Xin; Liu, Lin; Xu, Yajing; Wu, Dengshu; Zhang, Feng; Zhang, Jin; Wu, Liqing; Yin, Hewen; Lv, Binhua; Xiao, Zhijian; Jin, Jie |
| 2017 | Evaluation of the new Chinese Disseminated Intravascular Coagulation Scoring System in critically ill patients: A multicenter prospective study | Wu, Yingying; Luo, Lili; Niu, Ting; Han, Yue; Feng, Ying; Ding, Qiulan; Huang, Ruibin; Zhang, Xiaohui; Feng, Jianming; Hou, Ming; Peng, Jun; Li, Yan; Zhou, Yuhong; Su, Lei; Yang, Linhua; Zhou, Zeping; Xue, Feng; Gu, Jian; Zhu, Tienan; Wang, Xiaomin; Deng, Jun; Mei, Heng; Hu, Yu |
| 2018 | FINAL Results of an Phase, Multicenter, Randomied, Controlled OPEN LEVEL Trial: Decitabine Therapy in Patients with Myelodysplastic Syndromes | Shao, Zonghong; Liu, Hui; Jiang, Hao; Tong, Hongyan; Xiang, Ruixiang; Yang, Linhua; Zhao, Hongguo; Ouyang, Jian; Bai, Hai; Sun, Hui; Hou, Li; Jiang, Ming; Yun, Zeng; Liu, Zhuogang; Liang, Aibin; Xie, Yinghua; Yu, Kang; Zhai, Zhimin; Liu, Li |
| 2019 | A multicenter, prospective evaluation of the Chinese Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation | Luo, Lili; Wu, Yingying; Niu, Ting; Han, Yue; Feng, Ying; Ding, Qiulan; Huang, Ruibin; Zhang, Xiaohui; Feng, Jianming; Hou, Ming; Peng, Jun; Li, Yan; Zhou, Yuhong; Su, Lei; Yang, Linhua; Zhou, Zeping; Xue, Feng; Gu, Jian; Zhu, Tienan; Wang, Xiaomin; Deng, Jun; Mei, Heng; Hu, Yu |
| 25-Feb-2021 | A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia | Mei, Heng; Liu, Xiaofan; Li, Yan; Zhou, Hu; Feng, Ying; Gao, Guangxun; Cheng, Peng; Huang, Ruibin; Yang, Linhua; Hu, Jianda; Hou, Ming; Yao, Yazhou; Liu, Li; Wang, Yi; Wu, Depei; Zhang, Liansheng; Zheng, Changcheng; Shen, Xuliang; Hu, Qi; Liu, Jing; Jin, Jie; Luo, Jianmin; Zeng, Yun; Gao, Sujun; Zhang, Xiaohui; Zhou, Xin; Shi, Qingzhi; Xia, Ruixiang; Xie, Xiaobao; Jiang, Zhongxing; Gao, Li; Bai, Yuansong; Li, Yan; Xiong, Junye; Li, Runzi; Zou, Jianjun; Niu, Ting; Yang, Renchi; Hu, Yu |
| 5-Nov-2024 | Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China | Yuan, Mengyao; Zhou, Li; Du, Xin; Weng, Jianyu; Yang, Linhua; Ma, Yanping; Zhao, Shasha; Liu, Zhenfang; Wen, Qin; Bai, Qingxian; Feng, Xianqi; Han, Yanqiu; Li, Aifang; Liu, Chunshui; Leng, Qing; Meng, Li; Wang, Baohong; Ran, Xuehong; Wang, Xiaodong; Zhang, Haiguo; Zeng, Yun; Zhang, Yanli; Jiang, Qian |
| 5-Nov-2024 | Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications | Zhang, Yi; Zhou, Hu; Suo, Shanshan; Zhuang, Junling; Yang, Linhua; He, Aili; Liu, Qingchi; Du, Xin; Gao, Sujun; Li, Yarong; Li, Yan; Chen, Yuqing; Wu, Wen; Zhu, Huanling; He, Guangsheng; Hong, Mei; Jiang, Qian; Jiang, Zhongxing; Jing, Hongmei; Wang, Jishi; Xu, Na; Yue, Lingling; Zheng, Cuiping; Zhou, Zeping; Jin, Chenghao; Li, Xin; Liu, Lin; Xu, Yajing; Wu, Dengshu; Zhang, Feng; Zhang, Jin; Xiao, Zhijian; Jin, Jie |
| 1-Jun-2023 | A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF). | Zhang, Yi; Zhou, Hu; Zhuang, Junling; He, Aili; Li, Yarong; Yang, Linhua; Du, Xin; Gao, Sujun; He, Guangsheng; Hong, Mei; Jiang, Qian; Jiang, Zhongxing; Sun, Kai; Yue, Lingling; Zheng, Cuiping; Zhou, Zeping; Xiao, Zhi-Jian; Jin, Jie |
| Oct-2022 | Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naive patients with myelofibrosis: Results of a phase II trial | Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Wu, Liqing; Yu, Wenjuan; Jin, Jie |
| 2015 | Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL) | Wang, Jianxiang; Mi, Yingchang; Jiang, Bin; Chen, Xiequn; Ji, Chunyan; Li, Yan; Zhao, Xielan; Lai, Yongrong; Hu, Yu; Tang, Aiping; Liu, Ting; Jin, Jie; Li, Junmin; Yang, Linhua; Li, Jinyong; Meng, Fanyi |
| 2015 | Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL) | Wang, Jianxiang; Mi, Yingchang; Jiang, Bin; Chen, Xiequn; Ji, Chunyan; Li, Yan; Zhao, Xielan; Lai, Yongrong; Hu, Yu; Tang, Aiping; Liu, Ting; Jin, Jie; Li, Junmin; Yang, Linhua; Li, Jinyong; Meng, Fanyi |
| 5-Nov-2024 | Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with<i> CSF3R<SUP>T61sI</SUP></i> : A Multi-Centre Retrospective Study | Jiang, Qian; Xu, Na; Liu, Xiaoli; Meng, Li; Chen, Suning; Li, Jianyong; Yang, Linhua; Chen, Chun-Yan; Chen, Limei; Sun, Jie; Pan, Ling; Duan, Minghui; Jing, Hongmei; Ren, Jinhai; Lin, Fengru; Cui, Lijuan; Yuan, Xianhua; Qin, Xuemei; Xu, Junqing; Gale, Robert Peter; Zhao, Mingfeng; Pan, Zhilan; Xiao, Zhijian; Li, Weiming |
